
Shattuck Labs (STTK) Stock Forecast & Price Target
Shattuck Labs (STTK) Analyst Ratings
Bulls say
Shattuck Labs is a biotechnology company that has shown promising results with its lead drug, SL-325, targeting DR3 receptor for treating inflammatory bowel disease. The company's stock price has been adjusted based on its projected sales and valuation through clinical net present value model. Upcoming Phase 1 data for SL-325 is highly anticipated and is expected to contribute to a bullish outlook for the company, although potential risks still remain. Preclinical studies have shown positive results for SL-325, and its clinical trials will reveal its safety and efficacy. There is also potential for SL-325 to outperform other drugs targeting TL1A, depending on its immunogenicity and anti-drug antibodies.
Bears say
Shattuck Labs is facing strong competition in the field of developing DR3 inhibitors for IBD treatment, with promising results being shown by other companies such as XNCR's XmAb942. Additionally, while early studies have shown potential for SL-325, further research is needed to fully understand its efficacy and safety, and the company faces challenges in conducting successful clinical trials with varying primary endpoints and trial sizes. Overall, there is a level of uncertainty surrounding the success and market competitiveness of Shattuck Labs, leading to a negative outlook on the stock.
This aggregate rating is based on analysts' research of Shattuck Labs and is not a guaranteed prediction by Public.com or investment advice.
Shattuck Labs (STTK) Analyst Forecast & Price Prediction
Start investing in Shattuck Labs (STTK)
Order type
Buy in
Order amount
Est. shares
0 shares